US Is Land Of Opportunity For Zealand
Executive Summary
The Danish group is beefing up its operations across the Atlantic as it prepares filings for dasiglucagon and glepaglutide.
You may also be interested in...
Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
The latest drug development news and highlights from our US FDA Performance Tracker.
Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot
Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.